TEVA-RASAGILINE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

RASAGILINE (RASAGILINE MESYLATE)

から入手可能:

TEVA CANADA LIMITED

ATCコード:

N04BD02

INN（国際名）:

RASAGILINE

投薬量:

0.5MG

医薬品形態:

TABLET

構図:

RASAGILINE (RASAGILINE MESYLATE) 0.5MG

投与経路:

ORAL

パッケージ内のユニット:

30

処方タイプ:

Prescription

治療領域:

MONOAMINE OXIDASE B INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0151662001; AHFS:

認証ステータス:

APPROVED

承認日:

2013-12-13

製品の特徴

TEVA-RASAGILINE
Page 1 of 48
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVA-RASAGILINE
Rasagiline Mesylate Tablets
Tablets, 0.5 mg and 1 mg , Oral
ANTIPARKINSON AGENT
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario,
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
August 18, 2014
Date of Revision:
September 22, 2022
Submission Control Number: 263230
RECENT MAJOR LABEL CHANGES
TEVA-RASAGILINE
Page 2 of 48
2 Contraindications
09/2022
7 Warnings and Precautions
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
1
TABLE OF CONTENTS
................................................................................................................
2
PART I:
HEALTH PROFESSIONAL
INFORMATION...................................................................
4
1
INDICATIONS................................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics
............................................................................................................
4
2
CONTRAINDICATIONS...................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
...................................................................................
6
4.1
Dosing Considerations
........................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
..................................................... 6
4.4
Administration
...................................................................................................
7
4